|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Glimelius B, Ekström K, Hoffman K, Graf W,
Sjödén PO, Haglund U, Svensson C, Enander LK, Linné T, Sellström H
and Heuman R: Randomized comparison between chemotherapy plus best
supportive care with best supportive care in advanced gastric
cancer. Ann Oncol. 8:163–168. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thuss-Patience PC, Kretzschmar A, Bichev
D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G
and Reichardt P: Survival advantage for irinotecan versus best
supportive care as second-line chemotherapy in gastric cancer-a
randomised phase III study of the Arbeitsgemeinschaft
Internistische Onkologie (AIO). Eur J Cancer. 47:2306–2314. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kang JH, Lee SI, Lim DH, Park KW, Oh SY,
Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, et al: Salvage
chemotherapy for pretreated gastric cancer: A randomized phase III
trial comparing chemotherapy plus best supportive care with best
supportive care alone. J Clin Oncol. 30:1513–1518. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamada Y, Higuchi K, Nishikawa K, Gotoh M,
Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, et al:
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus
S-1 in chemotherapy-naive patients with advanced gastric cancer.
Ann Oncol. 26:141–148. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Diem S, Schmid S, Krapf M, Flatz L, Born
D, Jochum W, Templeton AJ and Früh M: Neutrophil-to-Lymphocyte
ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic
markers in patients with non-small cell lung cancer (NSCLC) treated
with nivolumab. Lung Cancer. 111:176–181. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Murakami Y, Saito H, Shimizu S, Kono Y,
Shishido Y, Miyatani K, Matsunaga T, Fukumoto Y and Fujiwara Y:
Neutrophil-to-lymphocyte ratio as a prognostic indicator in
patients with unresectable gastric cancer. Anticancer Res.
39:2583–2589. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ethier JL, Desautels D, Templeton A, Shah
PS and Amir E: Prognostic role of neutrophil-to-lymphocyte ratio in
breast cancer: A systematic review and meta-analysis. Breast Cancer
Res. 19:22017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Iwai N, Okuda T, Sakagami J, Harada T,
Ohara T, Taniguchi M, Sakai H, Oka K, Hara T, Tsuji T, et al:
Neutrophil to lymphocyte ratio predicts prognosis in unresectable
pancreatic cancer. Sci Rep. 10:187582020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ciocan A, Bolboacă SD, Drugan C, Ciocan
RA, Graur F and Al Hajjar N: Pattern of calculated inflammation
ratios as prognostic values in patients with colorectal cancer.
Comb Chem High Throughput Screen. 24:1428–1435. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bagley SJ, Kothari S, Aggarwal C, Bauml
JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson
JC, et al: Pretreatment neutrophil-to-lymphocyte ratio as a marker
of outcomes in nivolumab-treated patients with advanced
non-small-cell lung cancer. Lung Cancer. 106:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Caziuc A, Schlanger D, Amarinei G and
Dindelegan GC: Neutrophils-to-lymphocytes, lymphocytes to-monocytes
and platelets-to-lymphocytes ratios-predictive biomarkers for
response to neoadjuvant chemotherapy in breast cancer. J BUON.
25:182–187. 2020.PubMed/NCBI
|
|
15
|
Valero C, Lee M, Hoen D, Weiss K, Kelly
DW, Adusumilli PS, Paik PK, Plitas G, Ladanyi M, Postow MA, et al:
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden
as biomarkers of tumor response to immune checkpoint inhibitors.
Nat Commun. 12:7292021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bartley AN, Washington MK, Ventura CB,
Ismaila N, Colasacco C, Benson AB III, Carrato A, Gulley ML, Jain
D, Kakar S, et al: HER2 testing and clinical decision making in
gastroesophageal adenocarcinoma: Guideline from the college of
American pathologists, American society for clinical pathology, and
american society of clinical oncology. Arch Pathol Lab Med.
140:1345–1363. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Japanese Gastric Cancer Association, .
Japanese classification of gastric carcinoma: 3rd English edition.
Gastric Cancer. 14:101–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lauren P: The two histological main types
of gastric carcinoma: Diffuse and so-called intestinal-type
carcinoma. An attempt at a histo-clinical classification. Acta
Pathol Microbiol Scand. 64:31–49. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Templeton AJ, McNamara MG, Šeruga B,
Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G,
Knox JJ, Tran B, et al: Prognostic role of neutrophil-to-lymphocyte
ratio in solid tumors: A systematic review and meta-analysis. J
Natl Cancer Inst. 106:dju1242014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ock CY, Nam AR, Lee J, Bang JH, Lee KH,
Han SW, Kim TY, Im SA, Kim TY, Bang YJ and Oh DY: Prognostic
implication of antitumor immunity measured by the
neutrophil-lymphocyte ratio and serum cytokines and angiogenic
factors in gastric cancer. Gastric Cancer. 20:254–262. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou D, Wu Y, Zhu Y, Lin Z, Yu D and Zhang
T: The prognostic value of neutrophil-to-lymphocyte ratio and
monocyte-to-lymphocyte ratio in metastatic gastric cancer treated
with systemic chemotherapy. J Cancer. 11:4205–4212. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu H, Song M, Fang F, Gao X, Zhang Z and
Wang S: Prediction of chemotherapeutic efficacy using the ratio of
neutrophils to lymphocytes in patients with unresectable or
recurrent gastric cancer. Oncol Lett. 10:2244–2248. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang F, Liu ZY, Xia YY, Zhou C, Shen XM,
Li XL, Han SG, Zheng Y, Mao ZQ, Gong FR, et al: Changes in
neutrophil/lymphocyte and platelet/lymphocyte ratios after
chemotherapy correlate with chemotherapy response and prediction of
prognosis in patients with unresectable gastric cancer. Oncol Lett.
10:3411–3418. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McLellan P, Henriques J, Ksontini F, Doat
S, Hammel P, Desrame J, Trouilloud I, Louvet C, Pietrasz D,
Vernerey D and Bachet JB: Prognostic value of the early change in
neutrophil-to-lymphocyte ratio in metastatic pancreatic
adenocarcinoma. Clinics Res Hepatol Gastroenterol. 45:1015412020.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim JY, Jung EJ, Kim JM, Lee HS, Kwag SJ,
Park JH, Park T, Jeong SH, Jeong CY and Ju YT: Dynamic changes of
neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio
predicts breast cancer prognosis. BMC Cancer. 20:12062020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen LT, Satoh T, Ryu MH, Chao Y, Kato K,
Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, et al: A phase 3 study
of nivolumab in previously treated advanced gastric or
gastroesophageal junction cancer (ATTRACTION-2): 2-year update
data. Gastric Cancer. 23:510–519. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kumagai S, Togashi Y, Kamada T, Sugiyama
E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y,
Matsui S, et al: The PD-1 expression balance between effector and
regulatory T cells predicts the clinical efficacy of PD-1 blockade
therapies. Nat Immunol. 21:1346–1358. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kawakami H, Sunakawa Y, Inoue E, Matoba R,
Noda K, Sato T, Suminaka C, Sakamoto Y, Kawabata R, Ishiguro A, et
al: SO-8 Soluble programmed cell death ligand 1 associated with
clinical outcome in gastric cancer patients treated with nivolumab:
Blood based biomarker analysis of DELIVER trial (JACCRO-GC08AR).
Ann Oncol. 33:S3592022. View Article : Google Scholar
|
|
30
|
Ogata T, Satake H, Ogata M, Hatachi Y,
Inoue K, Hamada M and Yasui H: Neutrophil-to-lymphocyte ratio as a
predictive or prognostic factor for gastric cancer treated with
nivolumab: A multicenter retrospective study. Oncotarget.
9:34520–34527. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang Y, Gao P, Song Y, Sun J, Chen X, Zhao
J, Ma B and Wang Z: The prognostic nutritional index is a
predictive indicator of prognosis and postoperative complications
in gastric cancer: A meta-analysis. Eur J Surg Oncol. 42:1176–1182.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu J, Liu H, Zeng X, Zhao Y, Jiang D, Lu H
and Qian J: Prognostic and clinicopathological significance of
C-reactive protein/albumin ratio (CAR) in patients with gastric
cancer: A meta-analysis. PLoS One. 16:e02502952021. View Article : Google Scholar : PubMed/NCBI
|
